AssayIndex
Hypothalamic and posterior-pituitary hormones

Gonadorelin

GnRH · LHRH · Factrel · C55H75N17O13 · monoisotopic 1181.5825 Da. The index holds 49 assay reports on this compound across 10 batches from 8 suppliers.

49 reports10 batchesmedian 99.28 %index spec 98.5 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Native GnRH. The N-terminal pyroglutamate opens under acidic stress to give a +18 Da species 0.46 min early; that peak is the best available indicator of how harsh the final lyophilisation and any acid-salt exchange were. The index tracks gonadorelin closely because it is the only native hormone in this group and its impurity profile is therefore a clean readout of process rather than of design.

Molecular formula
C55H75N17O13
Monoisotopic mass
1181.5825Da
Average mass
1182.31Da
Residues
10
Nominal retention (RG-2, 30 min)
8.68min
Retention window
0.25min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 5 mg · 10 mg
Analytical difficulty (index scale)
0.85 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

030896177926612355 Gonadorelin8.68 min · 99.28 % 8.22 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Gonadorelin trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 99.28 % area at the nominal retention time of 8.68 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 49 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 99.28% n=49
Interquartile range 0.64pp n=49
Minimum 98.08% n=49
Maximum 99.93% n=49
Pass rate vs spec 91.8% n=49
Median recovery vs claim 96.2% n=25
Median water 4.95% n=49
Median |mass error| 2.9ppm n=40
036992.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=097.75–98.00 %: n=098.00–98.25 %: n=298.25–98.50 %: n=298.50–98.75 %: n=898.75–99.00 %: n=499.00–99.25 %: n=899.25–99.50 %: n=999.50–99.75 %: n=799.75–100.00 %: n=9median 99.28 Purity (% area) Reports
Figure 2. Purity distribution across all 49 Gonadorelin records. Dashed line is this compound's median (99.28 %); the solid vertical is the index acceptance specification for the hypothalamic and posterior-pituitary hormones class (98.5 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.998.398.699.099.499.7100.1TFCTFC: Q1 99.39, median 99.47, Q3 99.53, n=13outlier 98.97outlier 99.03outlier 99.81n=13MKMMKM: Q1 99.25, median 99.75, Q3 99.91, n=10n=10BCHBCH: Q1 98.60, median 98.62, Q3 98.94, n=9outlier 98.08n=9CPCCPC: Q1 98.54, median 98.66, Q3 99.17, n=5n=5SWBSWB: Q1 98.50, median 98.62, Q3 98.65, n=5outlier 98.97n=5ERPERP: Q1 99.46, median 99.57, Q3 99.70, n=4n=4SSASSA: Q1 99.93, median 99.93, Q3 99.93, n=2n=2 Purity (% area)
Figure 3. Gonadorelin purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
oxidised Trp (+16 Da)-0.32+15.99596%0.180.96
C-terminal free acid (+1 Da)+0.16+0.98494%0.081.06
ring-opened pGlu (+18 Da)-0.46+18.01192%0.181.12
des-Gly10-NH2 (−74 Da)-0.28-74.04890%0.141.06

Degradation pathways

  • pyroglutamate ring opening under acid
  • Trp oxidation

Full impurity profile, with what each named species implies about the synthesis →

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q11n<3—
2024-Q20n<3—
2024-Q3499.5799.28–99.93
2024-Q40n<3—
2025-Q10n<3—
2025-Q2598.6298.42–98.97
2025-Q3799.4799.18–99.93
2025-Q4998.6298.08–99.33
2026-Q1598.6698.46–99.49
2026-Q21899.5398.97–99.93
2026-Q30n<3—

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Gonadorelin records of 49.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042914MKMMKM-2604-A2596Janoshik2026-Q299.935.19—Supplier-supplied0PASS
AX-2026-042911MKMMKM-2604-A2596Medutest2026-Q299.085.55—Buyer-sourced1MARGINAL
AX-2026-042916MKMMKM-2604-A2596VendorInvestigate2026-Q299.364.91102.1Buyer-sourced1MARGINAL
AX-2026-042038TFCTFC-2511-E6450Janoshik2026-Q299.032.63101.8Supplier-supplied0PASS
AX-2026-042039TFCTFC-2511-E6450Janoshik2026-Q299.392.8196.2Supplier-supplied0PASS
AX-2026-042917MKMMKM-2604-A2596Kestrel2026-Q299.765.43105.7Buyer-sourced1MARGINAL
AX-2026-042944MKMMKM-2512-N3913PeptideMeter2026-Q299.925.7591.1Supplier-supplied0PASS
AX-2026-042033TFCTFC-2511-E6450PeptideMeter2026-Q299.482.96—Supplier-supplied1MARGINAL
AX-2026-042915MKMMKM-2604-A2596VendorInvestigate2026-Q299.035.2196.7Buyer-sourced0PASS
AX-2026-042035TFCTFC-2511-E6450Janoshik2026-Q299.532.0188.5Supplier-supplied1MARGINAL
AX-2026-042918MKMMKM-2604-A2596PeptideMeter2026-Q299.935.24—Supplier-supplied0PASS
AX-2026-042913MKMMKM-2604-A2596Nordanalyt2026-Q299.895.0798.0Supplier-supplied0PASS
AX-2026-042036TFCTFC-2511-E6450Janoshik2026-Q298.972.9492.0Laboratory-retained1MARGINAL
AX-2026-042037TFCTFC-2511-E6450Medutest2026-Q299.532.6693.2Supplier-supplied1MARGINAL
AX-2026-042919MKMMKM-2604-A2596PeptideMeter2026-Q299.744.78—Supplier-supplied0PASS
AX-2026-042034TFCTFC-2511-E6450Medutest2026-Q299.812.67—Supplier-supplied0PASS
AX-2026-042032TFCTFC-2511-E6450Janoshik2026-Q299.623.09—Supplier-supplied1MARGINAL
AX-2026-042912MKMMKM-2604-A2596Janoshik2026-Q299.215.07—Supplier-supplied1MARGINAL
AX-2026-043378CPCCPC-2508-B3242Nordanalyt2026-Q198.545.11—Supplier-supplied3MARGINAL
AX-2026-043376CPCCPC-2508-B3242VendorInvestigate2026-Q198.464.9597.8Buyer-sourced2FAIL
AX-2026-043375CPCCPC-2508-B3242Janoshik2026-Q199.174.36—Supplier-supplied3MARGINAL
AX-2026-043377CPCCPC-2508-B3242Janoshik2026-Q199.494.32106.5Supplier-supplied3MARGINAL
AX-2026-043379CPCCPC-2508-B3242Janoshik2026-Q198.665.3489.3Supplier-supplied4MARGINAL
AX-2026-043506BCHBCH-2510-F6239Janoshik2025-Q498.085.44—Buyer-sourced0FAIL
AX-2025-021211BCHBCH-2510-F6239Janoshik2025-Q498.915.56—Supplier-supplied1MARGINAL